V enous thromboembolism (VTE) comprised of deep vein thrombosis and pulmonary embolism is the third most common cardiovascular condition with an estimated annual incidence of 900,000 in the United States. 1 Close monitoring of the treatment (historically warfarin anticoagulation) is critical in these patients for preventing recurrent VTE and hemorrhage. Patients with VTE lacking health insurance have more constrained access to medications, anticoagulation clinics, primary care, and home care services. This constrained access can increase the rate of recurrent VTE and hemorrhage for patients with new episodes of VTE. In 2006, Massachusetts implemented landmark legislation which we will entitle "Health Reform" (in capitals throughout). The legislation improved access to these important care elements 2 and the utilization of health services in general. 3, 4 This legislation shifted government subsidies away from institutional-based support (Free Care funds provided to safety net hospitals and affiliated community health centers) into individual-based coverage through expanded Medicaid coverage and new insurance plan offerings similar to those currently offered nationally through insurance exchanges. 5 These new plans provide portable and comprehensive coverage, including access to local, retail pharmacies, and home care/visiting nurse services. Before Health Reform, patients covered by Free Care had access restricted to primary care, hospital care, and pharmacy at a safety net hospital or community health center. Accessing a safety net facility required patients to travel long distances as opposed to visiting a local facility. Complete coverage with Free Care was available to legal state residents making <200% of the federal poverty line; partial coverage was available for those making between 200% and 400% of the federal poverty line. 6 Whereas the benefits of Health Reform for individuals with VTE seem to be clear (ie, easier access to medication, outpatient visits, home care nursing), the cost implications are uncertain. Although the annual cost of Health Reform per individual was high-$3230 (adjusted to 2014 USD) per Free Care patient newly insured-the proportion attributable to VTE care and costs saved with avoiding hospitalizations related to VTE and hemorrhage events has not been studied. 5 The exact number of recurrent VTE or hemorrhage events for patients with Free Care is not available readily because of lack of databases which capture inpatient, ambulatory care, and laboratory care, such as would be necessary to compare stability of International Normalized Ratio (INR) 
METHODS
We constructed a decision tree and Markov model to estimate differences in cost and effectiveness between 2 strategies for providing anticoagulation to patients with a first VTE episode. In one strategy, we calculated the cost and effectiveness of providing anticoagulation in the context of insurance coverage with Health Reform. In the other strategy, coverage exists as Massachusetts previously provided through Free Care funds. We modeled a 5-year time horizon, a reasonable period over which to understand long-term implications of Health Reform on anticoagulation control, divided into 3-month cycles. By dividing our analysis into 3-month cycles, we only permit 1 event (recurrent VTE, hemorrhage, death) per cycle consistent with Markov modeling methodology. We believe this is reasonable given the overall low rate of any single event.
We assumed a health system economic perspective-including all direct costs, including hospital, outpatient, and pharmacy as well as all relevant health benefits related to VTE.
In Figure 1A , we depict the trajectory of patients with VTE who "enter the model," for the purpose of our analysis, in the acute anticoagulation health state and proceed from left to right (Fig. 1A) . Initially, in the base case, we assume that all patients are 50 years old, the average age of our patients at Boston Medical Center among those aged 18 to 64 years (ie, those eligible for Health Reform). After an initial mortality risk due to VTE or other causes, we sort patients into 3 therapeutic categories based on INR testing, the method used to determine whether patients are receiving the correct warfarin dose. INR values <2 indicate a subtherapeutic dose, values of 2-3 indicating a therapeutic dose, and values >3 indicating a supratherapeutic dose. After this branch point, patients could develop recurrent VTE or hemorrhage, with their probabilities depending on which therapeutic category applied. This is, in effect, how we operationalize the effect of Health Reform-more patients in the therapeutic range leading to fewer recurrent VTE and hemorrhage events (Fig. 1B) . If the net cost of the intervention is small or if the initial costs are offset completely by prevention of recurrent VTE and hemorrhage events, the health reform strategy will be cost-effective.
For each probability estimate we searched OVID Medline , spoke with experts, and reviewed the documents of authorities, such as the Centers for Disease Control and Prevention. For each parameter, we chose the highest quality evidence available but when there was uncertainty about the true value among equivalent data, we made a conservative choice that biased against the health reform strategy. To determine the effectiveness of Health Reform, we analyzed laboratory data of patients receiving anticoagulation at our home institution, Boston Medical Center and affiliated health centers from July 2000 until December 2011. More specifically, we determined the odds ratio (OR) of being subtherapeutic or supratherapeutic on warfarin for the newly insured compared with the prereform Free Care patients for a 3-month period (see Appendix, Supplemental Digital Content 1, http://links.lww.com/ MLR/B114 for more details). Because we found that the health reform strategy was neutral (ie, OR = 0.99) when considering the development of supratherapeutic INR levels, we focus our attention on the prevention of subtherapeutic INR levels. For the probability of recurrent VTE or new hemorrhage with anticoagulation initiation, we FIGURE 1. Decision analysis pathway for patient with new episode of VTE being treated with warfarin anticoagulation. A, Circles represent chance events, whereas triangles represent outcomes that lead to recursive, Markov model (B) death, VTE recurrent, VTE no AC, VTE acute. In the initial pathway depicted above, there is first a risk of death from background causes or VTE. In the next branch point, we segregate patients into relative probability of being supratherapeutic, subtherapeutic, or therapeutic based on data from Free Care patients before Health Reform versus patients previously on Free Care who became newly insured postreform. The therapeutic category determines the subsequent risk for more VTE or major bleeding depicted by the next set of branch points. Finally a patient can continue anticoagulation during the first 3-month cycle versus complete anticoagulation if already having completed 2 cycles (6 mo being the mean duration of therapy in our population). B, All patients start in the VTE acute state. After 3 months of anticoagulation, patients could end up in the well, death, VTE no AC (such as after intracranial bleeding), or VTE recurrent states. Thereafter, we assumed patients in the VTE recurrent state moved to the VTE chronic on AC state but could move back to VTE recurrent, could die (death state), or develop intracranial hemorrhage and then no longer receive anticoagulation (VTE no AC state). Next to each health state, we list the percentage of patients occupying that health state at the end of each 3-month cycle. Red values represent percentage of patients in health reform strategy and blue values represent percentage in no health reform strategy. We depict transitions possible in the next cycle with straight arrows until the 5-year mark at which point we no longer cycle patients and therefore have removed arrows. Before the 5-year mark, patients may also remain in the same state if no new event occurs; we represent this with circular arrows. To calculate cost-effectiveness of the health reform intervention we aggregate costs and QALYs accrued during each cycle according to which state the patient occupied. The cost-effectiveness can be calculated at each time point as the ICER which is the difference in cumulative costs divided by the difference in cumulative effectiveness. After 5 years, the health reform strategy cost approximately $1500 less and achieved 0.13 more QALYs compared with the no health reform strategy making it dominant compared with the no health reform strategy. Further details of the results of each of the 20, 3-month cycles available upon request made to the authors. AC indicates anticoagulation; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-years; VTE, venous thromboembolism.
Kapoor et al
Medical Care Volume 54, Number 5, May 2016 relied on a meta-analysis performed on a subset of studies in which patients with VTE received warfarin anticoagulation. 7 In this meta-analysis, the authors calculated the rate of VTE and bleeding stratified by therapeutic status of warfarin-that is, subtherapeutic, therapeutic, or supratherapeutic (Table 1 for further details).
Utilities and Tolls
We consulted the Tufts Cost-Effectiveness Analysis Registry to obtain the utility for patients with VTE on anticoagulation. Multiple publications with utilities derived from both standard gamble and time trade-off techniques suggested that the value is approximately 0.99 (ie, 1% difference from Well state). For acute VTE or hemorrhage events requiring hospitalization, we assess a toll as described in the Analysis section below.
Costs
We identified the incremental cost of health reform strategy based on the costs of shifting away from Free Care. 5 This equaled $791 million (adjusted to 2014 USD) to cover 245,000 Free Care patients, or approximately $3230 per person. As health insurance covers a wide range of services, to identify the share of Health Reform costs attributable to VTE, to derive the incremental cost of the health reform strategy, we measured the share of all health care costs attributable to VTE care using inpatient data compiled by the Agency for Healthcare Research and Quality. Specifically, we divided the total cost of VTE hospitalizations ($1.25 million) by the total cost of hospitalizations for all diagnoses ($309 million) for patients on Medicaid aged 45-64 in 2011 (given our base case assumption of treating a 50-y-old patient); this quotient suggested 0.32% of the health care dollar is attributable to VTE. Multiplying 0.32% by the added cost of an individual covered by Health Reform ($3230) resulted in an incremental cost of the health reform strategy attributable to VTE care of approximately $6. In sensitivity analysis, we varied this cost upto $10, based on variation of VTE and total cost components of the ratio.
We used Health Care Utilization Project discharge data for hospitalization costs related to VTE (mainly pulmonary embolism) and major hemorrhage. For outpatient costs of care, we used an analysis by Lin et al, 15 who, using 2008-2010 Medicare data, calculated VTE-related care costs for first and subsequent months of care after VTE, including warfarin costs. Costs are higher initially, as the difficulty of establishing a therapeutic warfarin level requires more provider visits. Although our source data might overestimate costs for younger Medicaid beneficiaries, we felt it was a fair approximation and then tested our assumption in sensitivity analysis.
We adjusted all costs to 2014 USD using the Medical Care Consumer Price Index for All Urban Consumers.
Analysis
First, we calculated costs and effectiveness accumulated for each 3-month cycle for each strategy. We then aggregated these over a total of 20 cycles, or 5 years. After An influential parameter included in Figure 2 .
z Data warehouse include clinical data from electronic medical record and billing data for patients seen at Boston Medical Center and affiliated health centers y Values chosen for this value and others in the table are not specifically those on Free Care or those without insurance as would be desired for the prereform context. Such data do not exist readily. 8 To calculate this probability we must convert the percentage of patients subtherapeutic if Free Care into a rate and then convert the odds ratio to a risk ratio and then multiply those 2 values. That results in a rate that we must then convert back into a probability.
z Computed by subtracting days lost in the hospital (using length of stay data from nationwide inpatient sample) from total number of days in cycle (ie, 365/4). the first year, we discounted both cost and effectiveness at 3% per year consistent with prevailing guidelines. 12, 17 To calculate effectiveness in quality-adjusted life-years (QALYs), we aggregate time spent in a health state by its associated utility. We then subtract this value by the tolls for days "lost" in the hospital with recurrent VTE and hemorrhage. This requires converting effectiveness of each strategy measured in QALYs into quality-adjusted life-days, subtracting by the number of days over which the patient is typically hospitalized for all events (essentially equating days in the hospital with no value), and then converting the difference back to QALYs to get a net effectiveness for each strategy. This follows standard practice. 18 We calculated the incremental cost-effectiveness ratio (ICER) as the difference in cost between strategies divided by the difference in their effectiveness measured in QALYs. We interpret this ratio as the cost to achieve an additional QALY. Policy makers are interested in the ICER value because it accounts for the possibility of less expensive or more efficient options available when selecting from competing programs. 19 In cases where a strategy cost less and is more effective than a comparator strategy, the first strategy is said to dominate the comparator. Although there exists no official threshold, $100,000/QALY is a threshold often cited above which decision analysts would claim an intervention not to be cost-effective. 20 Interventions < 50,000/QALY are generally costeffective and interventions with ICER between 50,000 and 100,000/QALY have an indeterminate cost-effectiveness.
We conducted 1-way analysis to assess the impact of uncertainty in individual parameters on the ICER for health reform. We also performed probabilistic sensitivity analysis, where the analyst assigns distributions for each parameter and then samples them simultaneously to assess the joint effect of input parameter uncertainty. More specifically, we constructed distributions for the important parameters in cases where parameter variation led to differences in results Z$5000/QALY in 1-way analysis following a prior example. 21 We simultaneously sampled from distributions for 9 variables that we found to be influential in 1-way sensitivity analysis. More specifically, we used b-distributions for probabilities, gamma distributions for costs, and lognormal distributions for relative risks following guidance in the literature 22 (technical appendix, Supplemental Digital Content 1, http://links.lww.com/MLR/B114 with actual distributions available upon request). To obtain a stable cost-effectiveness result, we ran the model 3 separate times for 20,000 iterations (ie, resampling the 9 distributions 20,000 times and putting those values into the model along with the constant value for the remaining variables).
We conducted all cost-effectiveness analyses in TreeAge Pro HealthCare 2014. 23 
RESULTS
In the base case 50-year-old patient, the health reform strategy cost $15 less and was 0.0013 QALYs more effective than the nonhealth reform strategy leading to an ICER = À 11,500 USD/QALY. Thus, health reform dominated the no health reform strategy. In Figure 1B , we tracked the trajectory of 100 patients with VTE eligible to benefit each year from Health Reform in Massachusetts. According to our results, by 5 years, in the health reform strategy, 18.3% will have died, 9.10% would be on anticoagulation for recurrent events, and 71.5% would have had no further events (Well state); by small contrast, in the no health reform strategy, the respective percentages would be 18.3%, 9.12%, and 71.5%. In a sensitivity analysis (Fig. 2) , the OR of Health Reform protecting against a subtherapeutic warfarin level (ie, Health Reform effectiveness) was the most influential parameter. At an OR > 0.86 (base case 0.78), Health Reform was no longer cost-saving (ICER > $0/QALY). At an ORZ0.95, Health Reform cost >$100,000/QALY gained. Another important variable was the yearly cost of insuring Free Care patients with Health Reform. At a cost of >$4800 (base case $3230) per person, Health Reform was no longer dominant and at $8000 it cost $45,168/QALY. Other important parameters include the percentage of costs attributable to VTE versus all care in Massachusetts, the 3-month probability of recurrent VTE when warfarin is therapeutic, the 3-month probability of being subtherapeutic on warfarin for Free Care patients before Health Reform, and the cost of a VTE admission.
In probabilistic sensitivity analysis, the health reform strategy was dominant (ie, ICER threshold <$0/QALY) in 61% of model iterations, cost <$50,000/QALY in 74% of iterations, and <$100,000/QALY, 78% of the time (Fig. 3) .
DISCUSSION
We found that health reform strategy cost less and was more effective than (ie, dominated) the no health reform strategy. Results were most sensitive to the odds that Health Reform was protective against a subtherapeutic warfarin level, Health Reform cost, and the percentage of total health care costs attributable to VTE. In probabilistic sensitivity analysis, the health reform strategy was dominant in 61% of simulations.
We are unaware of other economic analyses of health insurance reform with respect to patients with VTE. Our approach to modeling Health Reform effectiveness through the intermediate outcome of subtherapeutic anticoagulation is consistent with other cost-effectiveness analyses of anticoagulation management strategies. [24] [25] [26] Among them, Lafata et al 24 analyzed the role of INR patient self-testing (PST) compared with anticoagulation clinic-based care. They modeled the incremental cost as $107 annually, which was more costly than our intervention ($6). Their PST estimates suggested a >4-fold decrease in the probability of being subtherapeutic, which translates to an OR of 0.18 compared with our OR of 0.78. They therefore found PST dominant compared with anticoagulation clinic management. Their findings hinge on the inclusion of patient costs, which we did not include in our analysis. We believe patient costs would decrease through more convenient care (decreased transportation time and lost wages traveling to safety net hospital for outpatient care and medications) and that the health reform strategy would have been even more favorable with their inclusion but do not have direct evidence to support this suggestion.
There are significant implications to our findings. Although providing insurance only had a small savings in terms of VTE ($15 per person or approximately $6000/y for the state of Massachusetts based on our projection of approximately 400 patients with VTE who would be benefit from Health Reform), the aggregation of health savings across the multitude of conditions health reform would address would be sizable. Health Reform would likely be cost-effective or even cost-saving for conditions similar to anticoagulation which are sensitive to local pharmacy access and home nursing. These are the services afforded by comprehensive, portable health insurance that were not available to Free Care patients before Health Reform. Advanced congestive heart failure with its requirement for careful titration of diuretic and blood pressure medication could be another target condition which may be responsive to Health Reform. Similarly the effectiveness gained in the state of Massachusetts for VTE would be relatively small (0.52 QALYs/y), but across multiple conditions the impact would likely be substantial. In general, we should adopt proposed interventions that cost less and gain effectiveness compared with the status quo. 27 Health Reform falls into this category assuming what we found holds true across multiple other conditions. We welcome further investigation to replicate our approach in other conditions.
Beyond Massachusetts, health insurance reform may prove even more cost effective for patients requiring anticoagulation and other insurance-responsive conditions. The safety net system for Free Care patients that preceded Health Reform was relatively robust, particularly in the Boston area from where we sampled our laboratory data for establishing levels of subtherapeutic warfarin. To that point, the percentage of anticoagulation episodes associated with a subtherapeutic warfarin level in Free Care patients prereform was only 2 percentage points lower than in the insured prereform (20% vs. 22%) in our analysis (Table 1) . In other parts of Massachusetts and other states where safety net programs are less robust, benefits to VTE patients may be greater.
There are several limitations to our findings. We had no data on recurrent VTE and hemorrhage for patients in Free Care patients and newly insured populations used to measure Health Reform effectiveness. We measured effectiveness through the probability of being subtherapeutic on warfarin using data exclusively from Boston Medical Center and its affiliated community health centers. Capturing sufficient numbers of Free Care patients in Massachusetts over the duration of anticoagulation for measurement of definitive outcomes would be infeasible in the absence of all-payer outpatient claims data in Massachusetts covering the prereform and postreform periods. In our analysis, there is also a potential for confounding by indication. We rely on patients accessing health care in the form of INR testing and diagnosis of VTE to identify them. If Free Care patients with VTE did not come for testing, or came infrequently, we would not have captured them in our analyses. If we had a direct source for outcomes information, like an all-payer combined inpatient and outpatient claims database, we believe the rate would have been able to detect and even higher rates of recurrent VTE and hemorrhage among Free Care patients than we computed with the indirect method of assessing warfarin adherence.
Another limitation is that our results from Boston Medical Center may not be generalizable to health systems in other parts of Massachusetts. Boston Medical Center is the largest safety net hospital in Massachusetts and comprised a large proportion of Free Care patients and newly insured considered in our analysis. Although a single health system experience could be confounded by secular quality improvements, only quality control efforts specifically designed to assist newly insured patients preferential to commercial insurance patients could bias our findings. We are unaware of any such quality control efforts at Boston Medical Center over this time period. We measured the decreased risk of being subtherapeutic for the newly insured controlling for secular trends in the insured with a difference in differences approach. Our analysis is the first (of which we are aware) to demonstrate the effectiveness of Massachusetts Health Reform in a discrete medical condition using actual clinical data. Other studies compare Massachusetts state discharge, claims data with similar data from other states, and infer effectiveness through examining narrowing of disparities among vulnerable groups based on race and socioeconomic status. 28, 29 We welcome other studies exploring the impact of Health Reform on anticoagulation and other discrete medical conditions, particularly those sampling from multiple health systems using individual patient insurance information.
In addition, we must temper our conclusion that the health reform strategy was cost-effective based on the fact that even at $100,000/QALY only 78% of the simulations in probabilistic sensitivity analysis confirm that Health Reform was cost-effective. This is only 17% higher than the 61% of simulations for which Health Reform was dominant suggesting a relatively narrow window of values for some input parameters before our cost-effectiveness conclusions change. To this point, as the OR for Health Reform protecting against a subtherapeutic warfarin varied over a relatively narrow range (0.86-0.95) in sensitivity analysis, the cost-effectiveness result went from $0 upto $100,000/QALY. If more anticoagulation episodes could be analyzed, we could have used a narrower distribution for the OR parameter in the probabilistic analysis, perhaps causing fewer simulations in which the ICER was not cost-effective. Nevertheless, the rather small incremental effectiveness associated with the health reform strategy in the base case (0.0013 QALYs) makes the analysis quite sensitive to the variable of health reform protecting against a subtherapeutic warfarin level. The analysis is much less sensitive to other variables in the model. Moreover, in 61% of simulations, that is, the majority of the time, the health reform strategy dominated the no health reform strategy, a situation in which policy makers should generally adopt an intervention. 30 Finally, we recognize that the advent of new oral anticoagulants could change the cost-effectiveness of Health Reform. Another cost-effectiveness study 31 has already reported that rivaroxaban dominates warfarin suggesting that providing health insurance with access to rivaroxaban would also dominate not providing insurance. Many patients will still remain on warfarin and for those patients our result will still apply.
In conclusion, Massachusetts Health Reform cost less and was more effective than no health reform in the context of our base case patient with VTE and also in the majority of probabilistic sensitivity analysis simulations. Our results suggest that Health Reform might be cost-effective for other conditions with similar resource needs and in other areas of the state and nation in similar safety net hospital settings that would be affected by health insurance reform. Our analytic approach, which is adjusted for secular trends and performed extensive sensitivity analyses, bolsters the validity and robustness of these findings.
